PubRank

O Götze

Author PubWeight™ 133.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The C3-activator system: an alternate pathway of complement activation. J Exp Med 1971 7.07
2 C3 proactivator convertase and its mode of action. J Exp Med 1972 6.94
3 Lysis of erythrocytes by complement in the absence of antibody. J Exp Med 1970 3.19
4 Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med 1972 2.91
5 The role of properdin in the alternate pathway of complement activation. J Exp Med 1974 2.77
6 Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med 1976 2.66
7 Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med 1976 2.13
8 A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A 1976 2.09
9 The alternative pathway of complement activation. Adv Immunol 1976 1.87
10 Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry 1973 1.86
11 The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol 1976 1.67
12 Detection of circulating immune complexes in patients with glomerulonephritis. Kidney Int 1977 1.66
13 Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 2001 1.64
14 A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement. J Exp Med 1974 1.63
15 The induction of macrophage spreading by factor B of the properdin system. J Exp Med 1979 1.50
16 The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol 2006 1.50
17 Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin. J Immunol 1977 1.47
18 Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997 1.41
19 Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991 1.41
20 Regulation of macrophage migration by products of the complement system. Proc Natl Acad Sci U S A 1979 1.29
21 S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009 1.27
22 Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006 1.26
23 Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997 1.23
24 Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol 1991 1.22
25 Nephritic factor: its structure and function and its relationship to initiating factor of the alternative pathway. Scand J Immunol 1976 1.21
26 Complement utilization by guinea pig 1 and 2-immunoglobulins through the C3 activator system. J Immunol 1971 1.20
27 The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2. Blood 1997 1.17
28 Release of trapped marker from liposomes by the action of purified complement components. Proc Natl Acad Sci U S A 1969 1.16
29 Clustering of ligand on the surface of a particle enhances adhesion to receptor-bearing cells. J Biol Chem 1988 1.16
30 Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993 1.15
31 Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol 1995 1.14
32 Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int 1997 1.11
33 Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain. J Immunol 1993 1.10
34 C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol 1999 1.07
35 Activated human T lymphocytes express a functional C3a receptor. J Immunol 2000 1.04
36 Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol 2001 1.03
37 Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995 1.03
38 Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992 1.00
39 Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 2000 1.00
40 Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996 1.00
41 [Prevention of habitual abortion by buffycoat transfusions]. Z Geburtshilfe Perinatol 1986 0.98
42 The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. Immunology 1991 0.97
43 [S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease"]. Z Gastroenterol 2009 0.96
44 Rapid increases in the membrane expression of neutral endopeptidase (CD10), aminopeptidase N (CD13), tyrosine phosphatase (CD45), and Fc gamma-RIII (CD16) upon stimulation of human peripheral leukocytes with human C5a. J Immunol 1991 0.96
45 Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading. J Exp Med 1981 0.96
46 Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 1994 0.95
47 Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774. Eur J Immunol 1998 0.95
48 A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. Artif Organs 1995 0.95
49 Induction of functional anaphylatoxin C5a receptors on hepatocytes by in vivo treatment of rats with IL-6. J Immunol 2000 0.95
50 Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 1999 0.95
51 Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. FEBS Lett 1997 0.94
52 The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology 2000 0.94
53 Anaphylatoxin C5a actions in rat liver: synergistic enhancement by C5a of lipopolysaccharide-dependent alpha(2)-macroglobulin gene expression in hepatocytes via IL-6 release from Kupffer cells. J Immunol 2001 0.93
54 Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule. Scand J Immunol 1976 0.92
55 Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur J Clin Invest 1998 0.92
56 CD11b and CD11c antigens are rapidly increased on human natural killer cells upon activation. J Immunol 1991 0.91
57 Human monocyte spreading induced by factor B of the alternative pathway of complement activation. Cell Immunol 1980 0.91
58 Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis. Am J Med 1977 0.91
59 A novel protein polymorphism of human complement C7 detected by a monoclonal antibody. Immunogenetics 1992 0.90
60 CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. J Immunol 1996 0.90
61 C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol 1999 0.89
62 C7*9, a new frequent C7 allele detected by an allotype-specific monoclonal antibody. Complement Inflamm 1990 0.89
63 The human mast cell line HMC-1 expresses C5a receptors and responds to C5a but not to C5a(desArg). Scand J Immunol 1996 0.88
64 The biologic role of interleukin-8: functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. Blood 1999 0.88
65 Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cells. Histol Histopathol 2004 0.88
66 A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm 1991 0.88
67 Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies. Immunology 1991 0.88
68 Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology 2001 0.87
69 Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B. Klin Wochenschr 1988 0.87
70 Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. Kidney Int 1991 0.86
71 Determination of the epitope specificities of monoclonal antibodies using unprocessed supernatants of hybridoma cultures. J Immunol Methods 1990 0.86
72 Leucocyte counts and complement activation during pump-driven and arteriovenous haemofiltration. Contrib Nephrol 1983 0.86
73 Nephritic factor: Description of a new quantitative assay and findings in glomerulonephritis. Kidney Int 1976 0.85
74 Expression and induction of anaphylatoxin C5a receptors in the rat liver. Histol Histopathol 2003 0.85
75 Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. J Immunol Methods 1990 0.85
76 C3a(desArg) does not bind to and signal through the human C3a receptor. Immunol Lett 1999 0.84
77 Significant reduction of factor D and immunosuppressive complement fragment Ba by hemofiltration. Blood Purif 1996 0.84
78 Expression and regulation of complement factors H and I in rat and human cells: some critical notes. Mol Immunol 2001 0.84
79 Chemoattractant receptors for interleukin-8 and C5a: expression on peripheral blood leukocytes and differential regulation on HL-60 and AML-193 cells by vitamin D3 and all-trans retinoic acid. Eur J Immunol 1997 0.84
80 Defect of a complement receptor 3 epitope in a patient with systemic lupus erythematosus. J Clin Invest 1993 0.83
81 Specific detection by flow cytometry of histidine-tagged ligands bound to their receptors using a tag-specific monoclonal antibody. J Immunol Methods 1999 0.83
82 Assessment of complement activation in vivo. Immunopharmacology 1993 0.83
83 C5a receptors are detectable on mast cells in normal human skin and in psoriatic plaques but not in weal and flare reactions or in uticaria pigmentosa by immunohistochemistry. Arch Dermatol Res 1997 0.83
84 Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a(desArg) with a transient release of calcium via a pertussis toxin-sensitive signal transduction pathway. Eur J Immunol 1997 0.82
85 Comparative study of C5a plasma levels with different hemodialysis membranes using an enzyme-linked immunosorbent assay. Nephron 1989 0.82
86 The human mast cell line HMC-1 binds and responds to C3a but not C3a(desArg). Scand J Immunol 1998 0.82
87 Complement activation and depletion during LDL-apheresis by heparin-induced extracorporeal LDL-precipitation (HELP). Eur J Clin Invest 1991 0.81
88 Analysis of the tissue distribution of the rat C5a receptor and inhibition of C5a-mediated effects through the use of two MoAbs. Scand J Immunol 2000 0.81
89 [The 13C-methacetin breath test for quantitative noninvasive liver function analysis with an isotope-specific nondispersive infrared spectrometer in liver cirrhosis]. Dtsch Med Wochenschr 1998 0.81
90 Differential effects of human anaphylatoxin C3a on glucose output and flow in rat liver during orthograde and retrograde perfusion: the periportal scavenger cell hypothesis. Biochem Biophys Res Commun 1991 0.80
91 The isolation of B lymphocytes from human peripheral blood using antibodies coupled to paramagnetic particles and rosetting techniques. J Immunol Methods 1989 0.80
92 Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin. Ann Thorac Surg 1991 0.80
93 A novel ELISA for the assessment of classical pathway of complement activation in vivo by measurement of C4-C3 complexes. J Immunol Methods 1995 0.80
94 Anti-TNF treatment of baboons with sepsis reduces TNF-alpha, IL-6 and IL-8, but not the degree of complement activation. Scand J Immunol 1998 0.79
95 Human monocyte spreading induced by activated factor B of the complement alternative pathway: differential effects of Fab' and F(ab')2 antibody fragments directed to C5, C6, and C7. Cell Immunol 1983 0.79
96 Inhibition of anaphylatoxin C3a- and C5a- but not nerve stimulation- or Noradrenaline-dependent increase in glucose output and reduction of flow in Kupffer cell-depleted perfused rat livers. Hepatology 1996 0.79
97 A novel ELISA for the evaluation of the classical pathway of complement. J Immunol Methods 1998 0.79
98 Rat complement factor H: molecular cloning, sequencing and quantification with a newly established ELISA. Scand J Immunol 2002 0.79
99 Regulation of the human autologous T cell proliferation by endogenously generated C5a. Cell Immunol 1990 0.79
100 A sensitive ELISA for the quantitation of human C5a in blood plasma using a monoclonal antibody. Complement 1986 0.79
101 An improved fluorogenic substrate for the alternative complement pathway C3/5 converting enzyme CVFBb. Biochim Biophys Acta 1983 0.79
102 C7*N is a hypomorphic allele of the human complement c7 M/N protein polymorphism. Exp Clin Immunogenet 1991 0.78
103 [Life expectancy of patients with circulatory disorders of the posterior eyeball segment]. Ophthalmologica 1983 0.78
104 Immune haemolysis: reaction of the terminal complement component. Nature 1968 0.78
105 A fluorescent assay for complement activation. J Immunol 1981 0.78
106 Increase by anaphylatoxin C5a of glucose output in perfused rat liver via prostanoids derived from nonparenchymal cells: direct action of prostaglandins and indirect action of thromboxane A(2) on hepatocytes. Hepatology 1999 0.77
107 Molecular cloning and expression of the functional rat C5a receptor. Mol Immunol 1998 0.77
108 [The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema]. Anaesthesist 1996 0.77
109 Differential expression of the C5a receptor on the main cell types of rat liver as demonstrated with a novel monoclonal antibody and by C5a anaphylatoxin-induced Ca2+ release. Lab Invest 1999 0.77
110 Rat complement factor I: molecular cloning, sequencing and expression in tissues and isolated cells. Immunology 1999 0.77
111 Complement factor I is upregulated in rat hepatocytes by interleukin-6 but not by interferon-gamma, interleukin-1beta, or tumor necrosis factor-alpha. Biol Chem 2001 0.76
112 Recombinant generation of two fragments of the rat complement inhibitory factor H [FH(SCR1-7) and FH(SCR1-4)] and their structural and functional characterization in comparison to FH isolated from rat serum. Histol Histopathol 2006 0.76
113 Stimulation of glycogen phosphorylase in rat hepatocytes via prostanoid release from Kupffer cells by recombinant rat anaphylatoxin C5a but not by native human C5a in hepatocyte/Kupffer cell co-cultures. FEBS Lett 1995 0.76
114 Increase of glucose and lactate output and decrease of flow by human anaphylatoxin C3a but not C5a in perfused rat liver. FEBS Lett 1989 0.76
115 [Complement receptor 3 deficiency in systematic lupus erythematosus]. Immun Infekt 1992 0.75
116 [Immunotherapy of couples with habitual abortion]. Arch Gynecol Obstet 1989 0.75
117 Nucleotide and corrected amino acid sequence of the functional recombinant rat anaphylatoxin C5a. Biochim Biophys Acta 1997 0.75
118 Molecular aspects of the properdin system. Monogr Allergy 1977 0.75
119 Characterization of physiologic breakdown products of the complement fragment Ba. Mol Immunol 1994 0.75
120 Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes. Eur J Clin Invest 2001 0.75
121 The potential role of basophilic leukocytes and mast cells. Nephrol Dial Transplant 1994 0.75
122 Determination of the T3-3A1 antigen in PHA-induced human T-cells by standardized cell-ELISA. J Immunol Methods 1987 0.75
123 [Chest pain, dyspnea, discomfort with swallowing]. Praxis (Bern 1994) 2011 0.75
124 [Quantitative studies on the binding and agglutination capacity of A-immune antibodies of gamma-G and gamma-M types at different temperatures (4 degrees, 37 degree C)]. Z Immunitatsforsch Allerg Klin Immunol 1966 0.75
125 Stimulation by anaphylatoxin C5a of glycogen phosphorylase in rat hepatocytes via prostanoid release from hepatic stellate cells but not sinusoidal endothelial cells. FEBS Lett 1998 0.75